Introduction
============

As part of normal aging, the vitreous body liquefies and usually starts to separate from the posterior retina, described as posterior vitreous detachment. Incomplete separation at the macula is described as vitreomacular adhesion (VMA), which is not, in itself, pathological and is, by definition, not associated with morphological alterations of the retina or functional loss. In contrast, if residual, focal, vitreomacular tractional (VMT) forces lead to a distortion of retinal tissue, visual symptoms may occur. This condition is described as VMT (syndrome). In the course of VMT, the development of a full-thickness macular hole (MH) may be observed. In the literature, VMT, with or without MH, is often referred to as symptomatic VMA (sVMA).

Structural changes are usually best seen using optical coherence tomography (OCT) and are characterized by retinal distortion, intraretinal cysts, and foveal elevation. Full-thickness MHs may retain vitreous traction, or this may subsequently pull free. Both VMT and MH may resolve spontaneously, although this becomes increasingly unlikely with increasing size or longer duration of an MH.[@b1-opth-13-177]

Symptoms of sVMA typically include metamorphopsia and decreased distance and reading visual acuity,[@b2-opth-13-177] although some patients describe significant symptoms despite relatively well-preserved retinal structures. The indication of treatment of sVMA is usually based on the patients' complaints and function, and includes watchful waiting in less-pronounced cases, an intravitreal injection of a vitreolytic agent (ocriplasmin), or pars plana vitrectomy (PPV).[@b1-opth-13-177],[@b3-opth-13-177]

While the epidemiology of MHs is relatively well documented, this is not always broken down by MH stage or the presence or absence of vitreous adhesion. Therefore, combined with incomplete epidemiological data on VMT, the overall epidemiological burden of sVMA is unclear. To address this uncertainty, Jackson et al completed a systematic review regarding the epidemiology of sVMA,[@b4-opth-13-177] which was published 5 years ago. One may hypothesize that since then, figures may have changed due to an aging population and, even more important, higher-resolution OCT imaging being available. Based on the developments of high-resolution imaging, the staging of these conditions was revisited and new classification systems for sVMA and MHs have been suggested.[@b1-opth-13-177],[@b2-opth-13-177],[@b5-opth-13-177] However, for the present investigation, we used the MH classification published by the American Academy of Ophthalmology (AAO).[@b1-opth-13-177] Given this background, we aimed to update Jackson's analysis using international published data and then combine this with German vitrectomy data in order to estimate the burden of sVMA in Germany.

Materials and methods
=====================

Two systematic literature searches were conducted using the EMBASE and Medline databases and the Ovid interface. The first literature search targeted all eligible epidemiologic studies concerned with VMT and idiopathic MHs. The second collected all available data on MH staging and surgery in Germany. For the number of vitrectomies due to MH, we analyzed hospital data from the German national hospital reimbursement data.[@b6-opth-13-177]

Search for epidemiologic studies on VMT
---------------------------------------

In the first search, we used the following search terms in all search fields: vitreomacular traction, vitreoretinal traction, VMT, VMTS (vitreomacular traction syndrome), vitreomacular adhesion, vitreoretinal adhesion, VMA, vitreous AND macula AND separation, vitreous detachment, retinal detachment, macular detachment, macular hole, MH, retinal Hole, full-thickness macular hole, macular foramen and FTMH.

To filter for epidemiologic literature, we used the term "Epidemiology\[MeSH:NoExp\] OR Incidence\[Title/abstract\] OR Prevalence\[Title/abstract\] OR Epidemiology\[Title/abstract\]" as proposed by [Orphan.net](http://Orphan.net).[@b7-opth-13-177] The details of the search strategies are shown in [Table S1](#SD1-opth-13-177){ref-type="supplementary-material"}.

The search was conducted on February 19, 2018, by JM and AN, who independently sorted the articles and extracted the data. Differences were solved by discussion. To be included in the study, articles had to meet the inclusion and exclusion criteria listed in [Table 1](#t1-opth-13-177){ref-type="table"}.

MH stages in German vitrectomy patients
---------------------------------------

In the second search, we applied the following disease terms in all search fields: vitreomacular traction, vitreoretinal traction, VMT, VMTS, vitreomacular adhesion, vitreoretinal adhesion, macular hole, MH, Retinal Hole, full-thickness macular hole, macular foramen and FTMH. Defining the intervention, we used the terms "vitrectomy OR PPV OR pars plana OR surgery OR operation" in all fields and combined both searches using the AND operator.

The resulting set of articles was condensed by searching for the term "German" in all search fields. The search was conducted on February 19, 2018, by JM and AN, who independently selected the articles and extracted the data. Differences were resolved by discussion. The articles were sorted based on the inclusion and exclusion criteria listed in [Table 2](#t2-opth-13-177){ref-type="table"}. Search strategies are shown in detail in [Table S2](#SD2-opth-13-177){ref-type="supplementary-material"}.

Number of vitrectomies due to an MH in Germany
----------------------------------------------

We determined the number of PPVs in Germany in 2016 for a VMT using data from the Institut für das Entgeltsystem im Krankenhaus (InEK), the institute that facilitates reimbursement to hospitals. InEK collects all codes used by hospitals for billing of medical services.[@b6-opth-13-177] The codes used were ICD-10, Diagnosis Related Groups (DRG), and Operationen und Prozedurenschlüssel (OPS), all version 2016.

We filtered the data set for patients with the DRG codes C03A, C03B, or C03C indicating a retinal surgery. Two subsets were created using either the ICD-10 codes for macular pathology, H35.3 and H35.8, that include the diagnoses of VMT and MH, or the OPS codes for retinal surgery including macular manipulation 5-158.0, 5-158.1, 5-158.2, 5-158.4, 5-158.x, 5-158.y. The OPS codes included all relevant PPVs.[@b8-opth-13-177] Finally, we searched for patient numbers emerging in both DRG code subsets, created using either the ICD-10 codes or the OPS codes. Those patients matching both criteria (diagnosis defined by ICD and procedure defined by OPS) were assumed to have undergone vitrectomy due to an MH, VMT, and/or epiretinal membrane as well as some less-frequent macular diseases. Distribution of MH stages from the systematic literature research was applied to derive numbers for stage 1 and 2 MH.

Results
=======

VMT prevalence and incidence in population-based studies
--------------------------------------------------------

The systematic literature search for international epidemiologic studies resulted in 3,039 articles. This included 1,409 duplicates that were identified by review of the title and abstract and then removed. The abstract and title search resulted in 43 articles for full-text screening, of which 12 met the eligibility and were included ([Table 1](#t1-opth-13-177){ref-type="table"}). [Figure 1](#f1-opth-13-177){ref-type="fig"} shows the flowchart of the systematic literature search.

Seven publications reported epidemiologic data on VMT and five on MH. Study details are shown in [Table 3](#t3-opth-13-177){ref-type="table"}, listing design, population, sample size, diagnostic methods, and epidemiologic measures. With the exception of three studies,[@b9-opth-13-177]--[@b11-opth-13-177] all used OCT to diagnose VMT or MH. In most studies, the MH stage was not reported according to the current AAO classification.[@b1-opth-13-177]

All studies included quite large population samples, with varying estimates of VMT prevalence that are summarized in [Table 3](#t3-opth-13-177){ref-type="table"}. The incidence rate was estimated in only one study.[@b4-opth-13-177] For MH, both rates were estimated by at least three publications ([Table 1](#t1-opth-13-177){ref-type="table"}). From the given rates, we calculated the arithmetic average ([Table 3](#t3-opth-13-177){ref-type="table"}).

For VMT, we calculated from seven studies with a total of 18,859 participants (age range: 32--90 years) an average prevalence of 1.263 cases per 100,000. The incidence rate was reported by only one study with 0.56 cases per 100,000.[@b4-opth-13-177] Averaging the data of five studies with a total of 123,621 participants (age range: 26--90 years), we calculated an average prevalence for MH of 141 cases per 100,000 and an average annual incidence of 8.8 cases per 100,000.

We then aimed to refine these incidence and prevalence figures to consider just the subpopulation which had sVMA, namely, VMT with or without MH ([Table 4](#t4-opth-13-177){ref-type="table"}). All patients with a diagnosis of VMT were included, while those patients diagnosed with an MH only (72.8%) had a concomitant VMT according to Jackson's review of the literature.[@b4-opth-13-177] Therefore, the incidence and prevalence rates for MH were reduced to 72.8% of their reported values in [Table 4](#t4-opth-13-177){ref-type="table"} to capture only those MHs with coexisting VMT. The resulting prevalence rate, including all cases of VMT plus all MH cases with coexisting VMT, was 1.365 cases per 100,000 inhabitants with an incidence rate of 6.96 new cases per 100,000 inhabitants per year. Applied to the German population of roughly 82 million, every year, about 5,700 new cases of sVMA would be observed. From the literature, a prevalent pool of 1,119,300 patients is calculated.

MH stages in German vitrectomy patients
---------------------------------------

The literature search about MH stage rates in Germany resulted in 719 hits containing 159 duplicates. From these, 31 articles ([Table 3](#t3-opth-13-177){ref-type="table"}) were included. [Figure 2](#f2-opth-13-177){ref-type="fig"} shows the flowchart of the systematic literature search.

To estimate the surgical numbers for Germany based on real-world clinical data, we first made a literature search to determine the MH stage distribution of patients in Germany who underwent a PPV. Included studies are listed in [Table 5](#t5-opth-13-177){ref-type="table"}, indicating sample size and staging distribution. For evaluation, we pooled the patients of stages 3 and 4 and calculated the weighted average.

About 77% of all patients receiving a PPV for MHs in Germany had a stage 3 or 4 MH. Therefore, 23% had a stage 1 or 2 MH, including VMT.

Estimation of German VMT patients based on hospital surgery statistics
----------------------------------------------------------------------

According to the INEK data, 52,223 patients underwent retinal surgery in Germany in 2016 and 34,314 of these underwent a PPV base on OPS codes. Of the 52,223 patients, about 15,878 had ICD-10 codes H35.3 or H35.8, indicating any macular changes, including VMT and MH, but also including patients with surgery for other macular changes such as epiretinal membrane. Selecting patients in the overlap of the ICD-10 and OPS subgroups resulted in a sample of 9,941 patients. This group most likely included patients who underwent a PPV for MH or VMT, but due to nonspecific codes with the ICD-10 and OPS, it is likely that it also included patients with other macular diseases, in particular, epiretinal membrane.

Applying the stage distribution given in the literature ([Table 5](#t5-opth-13-177){ref-type="table"}) to these 9,941 patients, 7,655 patients had a stage 3 or 4 MH and 2,287 patients had an sVMA, that is, stage 1 or 2 MH and/or a VMT. Considering that not all MHs show concomitant VMT, only 72.8% of patients with MH had concomitant VMT,[@b4-opth-13-177] the numbers for stage 1 or 2 MHs and a VMT reduced to 1,665 vitrectomies for patients with VMT or MH stages 1 or 2 with VMT in Germany.

Discussion
==========

In the present work, we estimated the incidence and prevalence of VMT, with and without MH, based on 12 large international studies. We found a prevalence of 1,365 cases per 100,000 population and an incidence rate of 6.96 new cases per 100,000 population per year.

There is an apparent discrepancy between the incidence and prevalence rates, in that the prevalence is more than expected based on incident cases. There may be several reasons for this difference. First, the rate of spontaneous resolution of VMT (with or without MH) could be higher than previously assumed, and thus, only a small proportion of lesions that exist in the population-based studies (which drives our prevalence rates) progress to eye clinics/hospitals (which drives our incidence rates). This is possible as our understanding of the natural history of VMT and MH is largely based on clinical data, whereas the natural history of those outside of a clinic/hospital environment may differ. The use of OCT may also enable us to detect lesions much earlier than in previous studies, and earlier lesions might be more likely to resolve. Perhaps, the most likely explanation is that population-based studies may pick up asymptomatic cases that do not progress to intervention, unlike studies based on patients presenting to clinic or surgery.[@b12-opth-13-177]--[@b14-opth-13-177] More epidemiologic studies are needed to determine the sVMA incidence rates.[@b15-opth-13-177]

Given the existing uncertainties of results from the systematic literature review, we aimed to further validate our results with other data sources: As one validation step, we considered the number of MH patients predicted by the literature with an incidence rate for MHs of 8.8 patients per 100,000 adult inhabitants ([Table 1](#t1-opth-13-177){ref-type="table"}), suggestinĝ7,200 new MH patients for Germany per year. This is in good accordance with 2016 German vitrectomy statistics, which suggest that 9,941 patients received surgery for MH or VMT -- a figure that potentially also includes patients with other macular diseases, in particular, epiretinal membrane.

As another validation step, we considered a large vitreo-retinal database study in the UK,[@b4-opth-13-177] which reported that 40.2% of PPVs with macular manipulation were for MH. For the 34,314 German PPV patients with macular manipulation, the pool of MH patients would be 13,795, which is also in good accordance with the OPS/ICD filtered data figure of 15,878 patients. The same UK database study found that 14.2% of PPVs with macular manipulation were for VMT, suggesting that for Germany, 2,255 of the 15,878 vitrectomy patients with macular manipulation had VMT. These results are also concordant.

Weaknesses of this study include a reliance on certain assumptions. First, the AAO classification system describes stage 3 MHs (which we excluded) as those ≥400 µm in diameter with vitreomacular separation, but it is possible that some MHs \>400 µm still had persisting VMA. Also, clinicians may have applied the classification systems variably, as more than one has evolved over time.[@b1-opth-13-177],[@b3-opth-13-177],[@b16-opth-13-177] Further, the measurement of MHs and their classification may be subject to significant interobserver variability. The clinical statistic reflects in-patient settings with vitrectomy only, while intravitreal gas or air injections are documented by several case series as the possible out-patient therapy for sVMA.[@b17-opth-13-177]--[@b20-opth-13-177]

Conclusion
==========

While our estimated incidence of VMT (with and without MH) in Germany relies on a number of untested assumptions, it, nonetheless, shows that sVMA is an important disease affecting a large number of individuals, many of whom may be undiagnosed or exist outside of the clinic system.

Supplementary materials
=======================

###### 

International epidemiology search

  Databases: EMBASE 1974--2018; Medline(R) 1946--2018                                                                                             
  ----------------------------------------------------- ----------------------------------------------------------------------------------------- -----------
  \#1                                                   vitreomacular traction\*.af                                                               1,351
  \#2                                                   Vitreo macular traction\*.af                                                              60
  \#3                                                   VMT.af                                                                                    945
  \#4                                                   VMTS.af                                                                                   43
  \#5                                                   vitreomacular adhesion\*.af                                                               515
  \#6                                                   vitreo macular adhesion\*.af                                                              8
  \#7                                                   vitreous and macula\* and separation.af                                                   385
  \#8                                                   VMA.af                                                                                    2,970
  \#9                                                   (vitreo-macular traction\* or vitreoretinal traction\* or vitreo-retinal traction\*).af   623
  \#10                                                  (vitreo-macular adhesion\* or vitreoretinal adhesion\* or vitreo-retinal adhesion).af     299
  \#11                                                  macular hole\*.af                                                                         8,139
  \#12                                                  (retinal Hole\* or retinal break\*).af                                                    3,126
  \#13                                                  Vitreous detachment\*.af                                                                  3,080
  \#14                                                  Retinal detachment.af                                                                     44,383
  \#15                                                  macular detachment\*.af                                                                   1,317
  \#16                                                  (Macula hole\* or FTMH).af                                                                4,774
  \#17                                                  1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16       57,973
  \#18                                                  (epidemiology or incidence or prevalence).af                                              5,210,928
  \#19                                                  17 and 18                                                                                 3,778
  \#20                                                  limit 19 to yr="1996--2018"                                                               3,039

###### 

German epidemiology search

  Databases: EMBASE 1974--2018 week 9, Medline 1947 to week 4, 2018, Medline Epub ahead of print, in-process, and other non-indexed citation 2014 to present                                                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------- ------------
  \#1                                                                                                                                                          ((vitreomacula\* or vitreoretinal or vitreo-macula\* or vitreo macula\* or vitreo retinal) and traction).af               2,553
  \#2                                                                                                                                                          (VMT or VMTS).af                                                                                                          983
  \#3                                                                                                                                                          (vitreomacula\* adhesion\* or vitreo macula\* adhesion\*).af                                                              541
  \#4                                                                                                                                                          (macula\* Hole\* or macula\* foramen or FTMH).af                                                                          9,071
  \#5                                                                                                                                                          \#1 OR \#2 OR \#3 OR \#                                                                                                   11,446
  \#6                                                                                                                                                          (vitrectomy or ppV or pars plana or surgery or operation).af                                                              7,536,471
  \#7                                                                                                                                                          \#5 AND \#6                                                                                                               7,882
  \#8                                                                                                                                                          (((prospective or retrospective or cohort or observational or prognostic) and trial) or analysis or study or factor).af   28,747,371
  \#9                                                                                                                                                          \#14 AND \#13                                                                                                             4,499
  \#10                                                                                                                                                         German\$.af                                                                                                               6,094,077
  \#11                                                                                                                                                         10 AND 9                                                                                                                  719
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###### 

Exclusion and inclusion criteria for epidemiologic papers in VMT and MH

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Criterion             Inclusion criteria                                                                                  Exclusion criteria
  --------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Population            I1: Adult patients with VMT                                                                         E1: No adult patients with VMT

  Indication            I2: Treatment of VMT in adults, also together with a macular hole equal to or smaller than 400 µm   E2: No treatment of VMT in adults, also together with a macular hole equal to or smaller than 400 µm

  End points            I3: Epidemiologic measures\                                                                         E3: No epidemiologic measure
                        • Incidence\                                                                                        
                        • Prevalence                                                                                        

  Type of publication   I4: Full-text publications                                                                          E4: Publications, where no full text is available (eg, conference abstracts, letters)

  Type of study         I5: Epidemiologic survey                                                                            E5: Case studies, small case series, or studies not representative for the respective population

  Date of publication   I6: After 1996                                                                                      E6: Before 1996

  Language              I7: German or English                                                                               E7: Other languages
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** MH, macular hole; VMT, vitreomacular traction.

###### 

Exclusion and inclusion criteria for German studies on MH staging among the German patient population

  Criterion             Inclusion criterion                         Exclusion criterion
  --------------------- ------------------------------------------- --------------------------------------------------------------------------------------------------
  Population            I1: Adult patients for vitrectomy           E1: No adult patients for vitrectomy
  Intervention          I2: Vitrectomy                              E2: No vitrectomy
  Staging               I3: Macular hole staging (after Gass/AAO)   E3: No macular hole staging (after Gass/AAO)
  Type of publication   I4: Full-text publications                  E4: Publications, where no full-text is available (eg, conference abstracts, letters)
  Type of study         I5: Epidemiologic survey                    E5: Case studies, small case series, or studies not representative for the respective population
  Language              I7: German or English                       E7: Other languages
  Sample size           I8: Patient number ≥5                       E8: Patient number \<5
  Nationality           I9: German patients                         E9: No German patients

**Abbreviations:** AAO, American Academy of Ophthalmology; MH, macular hole.

###### 

Summary of epidemiologic studies on vitreomacular traction and MH, giving the average weighted rates of prevalence and incidence from all studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No                       Reference                                                               Design                                                                      Population, age span                                                                                                                                 Diagnostic methods                                    Prevalence rate (bold: normalized to 100,000 inhabitants)                                                                                                                                                                                                                                                      Incidence rate (bold: normalized to 100,000 inhabitants)        Remarks
  ------------------------ ----------------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------
  **VMT**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  1                        Jacob et al, 2016[@b12-opth-13-177]                                     Cross-sectional study, 2013                                                 N=481, 34--66 years Randomly chosen adult Belgians in a public hospital during open door day                                                         Cirrus 5000 OCT                                       **VMT with retinal distortion 1,170, VMT with retinal cysts 390**\                                                                                                                                                                                                                                             --                                                              
                                                                                                                                                                                                                                                                                                                                                                                          VMT prevalence for age \<50 years=0; for age \>50 years: VMT "grade 1" (fovea distortion)=1.17% (3 eyes), VMT "grade 2" (with pseudocysts)=0.39% (1 eye)                                                                                                                                                                                                                       

  2                        Jackson et al, 2013[@b4-opth-13-177]                                    Retrospective data analysis 2002--2010                                      N=8,741, 32.4--89.2 years 11,618 vitreoretinal operations of 9,619 eyes (8,741 patients) from 27 hospitals (age 32.4--89.2 years, median: 65)        Intraoperative                                        **(22.5[a](#tfn3-opth-13-177){ref-type="table-fn"} -- not included in the average)**\                                                                                                                                                                                                                          **0.56[a](#tfn3-opth-13-177){ref-type="table-fn"} VMT cases**   
                                                                                                                                                                                                                                                                                                                                                                                          1.5% of 11,618 operations (n=174), that is, 1.6% of eyes (n=167) were due to a VMT                                                                                                                                                                                                                                                                                             

  3                        Liesenborghs et al, 2018[@b21-opth-13-177]                              Prospective observational cohort study 2010--2013                           N=2,660, 40--75 years Randomly chosen subjects                                                                                                       OCT                                                   **1,900 VMT retinal changes**\                                                                                                                                                                                                                                                                                 --                                                              "VMT" without retinal changes could be "VMA". Symptoms were not specified
                                                                                                                                                                                                                                                                                                                                                                                          Of 2,660 subjects, 183 (6.9%) were diagnosed with a VMT. Of these, 51 (1.9%) had a VMT with retinal changes (elevations or cysts) No MHs were diagnosed; MH prevalence was 0%                                                                                                                                                                                                  

  4                        McKibbin et al, 2017[@b22-opth-13-177] "UK Biobank"                     Database study. Patients with VRIA were identified in the British Biobank   2,090, 40--69 years Of 133,668 registered subjects, 8,359 had visual impairments, of which 2,090 were included in the study. Mean age was 61 years   OCT (Topcon 1000), Funduscopy                         **870 VMT cases with visual impairment**\                                                                                                                                                                                                                                                                      --                                                              Small difference in the VMT frequency for eyes with and without impairment
                                                                                                                                                                                                                                                                                                                                                                                          For the 1,684 patients with monocular visual impairment, the VMT prevalence at the fovea was 0.87% (n=14); extrafoveal "VMT" was 0.62%[b](#tfn4-opth-13-177){ref-type="table-fn"} (n=10) For controls without visual impairment (n=472), the VMT prevalence for both VMT types was 0.65% (n=4), respectively                                                                   

  5                        Meuer et al, 2015[@b13-opth-13-177] "Beaver Dam" Study 20-year Update   Prospective cohort study 2008--2010 (Beaver Dam)                            1,540, \>43 years                                                                                                                                    Spectral-domain OCT                                   **1,600 VMT cases**\                                                                                                                                                                                                                                                                                           --                                                              VMA had a higher prevalence with 26% (551 eyes of 400 participants) After age adjustment, no difference between the sexes
                                                                                                                                                                                                                                                                                                                                                                                          VMT prevalence was 1.6% (28 eyes of 24 subjects from 1,540 participants)                                                                                                                                                                                                                                                                                                       

  6                        Rodman et al, 2017[@b14-opth-13-177]                                    Prospective, cross-sectional study 2012--2014                               1,090, 40--89 years Patients from 14 centers. Included were patients who attended for routine eye examination Age \>40 years, average: 56.2±9.7      Spectral-domain OCT                                   **1,100 VMT cases**\                                                                                                                                                                                                                                                                                           --                                                              VMA more frequent with 38.8% (756 eyes)
                                                                                                                                                                                                                                                                                                                                                                                          Prevalence of VMT 1.1% of all eyes (n=21 of 1.950 eyes)                                                                                                                                                                                                                                                                                                                        

  7                        Zapata et al, 2017[@b23-opth-13-177]                                    Cross-sectional study 2015--2016                                            2,257, age 45--90 years Participants at 17 centers (4,490 eyes), age \>45 years. Average: 59.5 years                                                 Spectral-domain OCT or swept-source OCT               **600 VMT cases**\                                                                                                                                                                                                                                                                                             --                                                              VMA more frequent with 29.3% (1,317 eyes)
                                                                                                                                                                                                                                                                                                                                                                                          VMT prevalence 0.6% (n=14 of all participants)                                                                                                                                                                                                                                                                                                                                 

  **Total participants**   **18,859**                                                              **Arithmetic average[b](#tfn4-opth-13-177){ref-type="table-fn"}**           **1,263**                                                                                                                                            **0.56[a](#tfn3-opth-13-177){ref-type="table-fn"}**                                                                                                                                                                                                                                                                                                                                                                                  

  **MH**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  8                        Darian-Smith et al, 2016[@b24-opth-13-177]                              Retrospective consecutive case series of a surgeon 2005--2011               136, age 26--90 years stage 2--4 MH at one Australian (Tasmanian) center (age: 69±8.8)                                                               OCT                                                   --                                                                                                                                                                                                                                                                                                             **4.05**\                                                       The analysis covered all cases of the complete Tasmanian population
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Incidence for idiopathic, FTMH                                  

  9                        la Cour and Friis, 2002[@b10-opth-13-177] Beaver Dam Study              Prospective cohort study (Beaver Dam) cp. Meuer et al, 2015                 4,802, 43--84 years Beaver Dam Study data Patients \>42 years Span 43--84 years                                                                      Funduscopy                                            **140 cases**\                                                                                                                                                                                                                                                                                                 **30 cases**\                                                   Beaver Dam 10-year incidence 0.7% (R Klein, personal communication)
                                                                                                                                                                                                                                                                                                                                                                                          Prevalence MH 0.3% -- age-normalized prevalence 0.14%                                                                                                                                                                                                                                                          Incidence MH 300 cases per 1 million per year                   

  10                       Mccannel et al, 2009[@b25-opth-13-177]                                  Retrospective chart review 1992--2002                                       106,470, 48--90 years                                                                                                                                Clinic, sometimes OCT                                                                                                                                                                                                                                                                                                                                                **7.8 cases**\                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Incidence of idiopathic MH in Olmstead, Minnesota               

  11                       Sen et al, 2008[@b9-opth-13-177]                                        Cross-sectional study, 2008                                                 7,774, \>40 years Average: 53.93±10.41 years                                                                                                         Funduscopy and fundus photography                     **170 cases**\                                                                                                                                                                                                                                                                                                 --                                                              
                                                                                                                                                                                                                                                                                                                                                                                          Prevalence MH 0.17% (=13 subjects)                                                                                                                                                                                                                                                                                                                                             

  12                       Wang et al, 2006[@b11-opth-13-177] ("Beijing" Study)                    Cross-sectional study 2006                                                  4,439, \>40 years representative participants aged \>40 years (8,653 eyes), age 55.9±10.4 years, one center                                          Fundus photography                                    Prevalence of FTMH was 0.09%±3.04% eyes (8 eyes of 7 patients), 95% CI=0.03%--0.16%                                                                                                                                                                                                                            --                                                              

  **Total participants**   **123,621**                                                             **Arithmetic average[b](#tfn4-opth-13-177){ref-type="table-fn"}**           **141**                                                                                                                                              **8.8**                                                                                                                                                                                                                                                                                                                                                                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Only cases treated with vitrectomy. Calculation from Simpson and Jackson:[@b26-opth-13-177] 2.1% of all vitrectomies due to VMT. Total vitrectomies=16,500 per year in Great Britain with 62.3 Mio inhabitants results in 0.56 cases per 100,000. The publication estimate for VMT including MH prevalence was 1,574 cases and the incidence was 31.3 cases per 100,000 inhabitants.

Weighted average, that is, average of all groups adjusted to the size of the study population. Larger studies impact the average more.

**Abbreviations:** FTMH, full-thickness macular hole; MH, macular hole; OCT, optical coherence tomography; VMA, vitreomacular adhesion; VMT, vitreomacular traction; VRIA, vitreoretinal interface abnormalities.

###### 

Summary of calculation of the prevalence and incidence of VMT from the literature estimates for VMT and MH

  Staging           Population applicable (%)   VMT prevalence (per 100,000 inhabitants)[a](#tfn6-opth-13-177){ref-type="table-fn"}   VMT incidence (per 100,000 inhabitants)[a](#tfn6-opth-13-177){ref-type="table-fn"}
  ----------------- --------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  VMT: All stages   100                         1,263                                                                                 0.56
  MHs               72.8                        102                                                                                   6.4
  Sum                                           1,365                                                                                 6.96

**Note:**

Calculated from weighted values found in the studies identified in the systematic literature search.

**Abbreviations:** MH, macular hole; VMT, vitreomacular traction.

###### 

German studies on staging MH patients undergoing PPV surgery

  No   Author, year                                     Study design                 Patient number   Stage distribution in %   Patients in % MH \>400 µm                   
  ---- ------------------------------------------------ ---------------------------- ---------------- ------------------------- --------------------------- ------- ------- -------
  1    Beutel et al, 2007[@b27-opth-13-177]             Randomized clinical trial    40               0.0                       5.0                         77.5    17.5    95.0
  2    Bopp et al, 1997[@b28-opth-13-177]               Prospective study            50               2.0                       22.0                        60.0    16.0    76.0
  3    Brockmann et al, 2011[@b29-opth-13-177]          Prospective study            25               12.0                      24.0                        36.0    28.0    64.0
  4    Brockmann et al, 2013[@b30-opth-13-177]          Retrospective study          160              0.0                       6.9                         37.5    55.6    93.1
  5    Eckardt et al, 2008[@b31-opth-13-177]            Prospective study            33               0.0                       45.5                        27.3    27.3    54.6
  6    Eckardt and Eckardt, 1995[@b32-opth-13-177]      Prospective study            37               5.4                       48.6                        35.1    10.8    45.9
  7    Engelmann et al, 2015[@b33-opth-13-177]          Retrospective study          45               0.0                       6.7                         13.3    80.0    93.3
  8    Faude et al, 1997[@b34-opth-13-177]              Prospective study            19               0.0                       21.1                        57.9    21.1    79.0
  9    Gass et al, 2003[@b35-opth-13-177]               Retrospective cohort study   18               5.6                       0.0                         88.9    5.6     94.5
  21   4.8                                              0.0                          71.4             23.8                      95.2                                        
  17   5.9                                              0.0                          82.4             11.8                      94.2                                        
  10   Gehring et al, 1999[@b36-opth-13-177]            Randomized clinical trial    19               0.0                       21.1                        47.4    31.6    79.0
  11   Göbel et al, 2000[@b37-opth-13-177]              Retrospective cohort study   36               0.0                       33.3                        50.0    16.7    66.7
  12   Göbel and Guthoff, 2010[@b38-opth-13-177]        Retrospective cohort study   10               0.0                       10                          70.0    20.0    90.0
  13   Hager et al, 2005[@b39-opth-13-177]              Retrospective cohort study   137              0.0                       0.0                         100.0   100.0   
  14   Haritoglou et al, 2001[@b40-opth-13-177]         Prospective cohort study     105              0.0                       7.6                         78.1    14.3    92.4
  15   Haritoglou et al, 2006[@b41-opth-13-177]         Prospective study            14               0.0                       0.0                         100     100.0   
  16   Hillenkamp et al, 2007[@b42-opth-13-177]         Retrospective cohort study   28               0.0                       28.6                        71.4    71.4    
  17   Hoerauf et al, 2001[@b43-opth-13-177]            Prospective study            44               0.0                       27.3                        47.7    25.0    72.7
  18   Jenisch et al, 2017[@b44-opth-13-177]            Retrospective study          225              0.0                       52.0                        32.0    16.0    48.0
  19   Jordan et al, 2012[@b45-opth-13-177]             Prospective study            26               15.4                      23.1                        38.5    23.1    61.6
  20   Krömer et al, 2004[@b46-opth-13-177]             Prospective study            20               0.0                       0.0                         100.0   0.0     100.0
  21   Kristin et al, 2001[@b47-opth-13-177]            Prospective study            78               0.0                       7.7                         76.9    15.4    92.3
  22   Kube et al, 2002[@b48-opth-13-177]               Retrospective cohort study   107              0.0                       63.6                        33.6    2.8     36.4
  23   Mayer et al, 2014[@b49-opth-13-177]              Prospective study            16               0.0                       0.0                         37.5    62.5    100.0
  24   Meyer et al, 2008[@b50-opth-13-177]              Prospective study            91               0.0                       12.1                        56.1    31.8    87.9
  25   Rüfer et al, 2007[@b51-opth-13-177]              Retrospective cohort study   61               0.0                       11.5                        77.0    11.5    88.5
  26   Remy et al, 2008[@b52-opth-13-177]               Retrospective cohort study   14               0.0                       28.6                        35.7    35.7    71.4
  27   Schrader and Schrenker, 1999[@b53-opth-13-177]   Prospective study            39               0.0                       20.5                        79.5    79.5    
  28   Schumann et al, 2007[@b54-opth-13-177]           Retrospective cohort study   96               0.0                       0.0                         80.2    19.8    100.0
  29   Wirbelauer et al, 2011[@b55-opth-13-177]         Prospective study            21               0.0                       25.0                        75.0    0.0     75.0
  30   Wirbelauer et al, 2016[@b56-opth-13-177]         Prospective study            47               0.0                       36.2                        63.8    0.0     63.8
  31   Wolf et al, 2003[@b57-opth-13-177]               Retrospective cohort study   37               0.0                       35.1                        56.8    8.1     64.9

**Notes:** Proportion of vitrectomized patients with an MH at stages 3 and 4, arithmetic average=79.6%. Proportion of vitrectomized patients with an MH at stages 3 and 4, weighted average=77.5%.

**Abbreviations:** MH, macular hole; PPV, pars plana vitrectomy.
